Multiple sclerosis (MS), a progressive, neurodegenerative, immune-mediated neurological disease that afflicts people with irreversible physical disability and functional impairment. Along with the physical toll, it exacts a substantial economic burden, which includes direct and indirect costs. This paper provides an update to the April 2016 paper Multiple Sclerosis: New Perspectives on the Patient Journey, adding more recent data and methodologies. It also offers a snapshot analysis for the year 2015 and a longitudinal analysis spanning 2006 to 2017.

This report was commissioned by Biogen.